OBJECTIVE： To investigate the effects of Tongxinluo capsules on the levels of serum cyclophilin A （CyPA） and matrix metalloproteinase-9 （MMP-9） in patients with coronary heart disease （CHD） after percutaneous coronary intervention （PCI）. METHODS： A total of 115 CHD patients undergoing PCI were randomly divided into control group （59 cases） and observation group （56 cases）. Control group was given conventional treatment. Observation group was additionally given Tongxinluo capsules 0.78 g， 3 times a day， for consecutive 6 months， on the basis of control group. The levels of CyPA and MMP-9 as well as the occurrence of ADR were observed in 2 groups before and after treatment. RESULTS： Before treatment， there was no statistical significance in serum level of CyPA and MMP-9 between 2 groups （P＞0.05）. The levels of CyPA in 2 groups 1 d and 1 month after surgery as well as the level of CyPA in control group 6 months after surgery were all significantly higher than before surgery， but the observation group was significantly lower than the control group 1 and 6 months， this index was decreased gradually as time， with statistical significance （P＜0.05）. There was no statistical significance in the levels of CyPA between 2 groups 1 d after surgery or in observation group between 6 months after surgery and before surgery （P＞0.05）. The levels of MMP-9 in 2 groups 1 d and 1 month after surgery were significantly higher than before surgery， and the observation group was significantly lower than the control group， this index was decreased gradually as time， with statistical significance （P＜0.05）. There was no statistical significance in the levels of MMP-9 of 2 groups between 6 months after surgery and before surgery（P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Tongxinluo capsules can significantly reduce the levels of CyPA and MMP-9 in CHD patients after PCI.